MedPath

Observational Study on the long term prognosis in A Multicenter Phase II Clinical Study Evaluating the Efficacy and Safety of Neoadjuvant and Adjuvant Chemotherapy with Encorafenib, Binimetinib Plus Cetuximab in Patients with Surgically Resectable BRAF V600E Mutant Colorectal Metastasis

Not Applicable
Recruiting
Conditions
Patients with surgically resectable BRAF V600E mutant colorectal metastasis.
Registration Number
JPRN-UMIN000050148
Lead Sponsor
ational Cancer Center Hospital East
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
44
Inclusion Criteria

Not provided

Exclusion Criteria

Patients whose consent has not been withdrawn will be included.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath